Lab guide · Growth-hormone axis
Mis on ipamoreliin? Ülevaade greliini retseptori agonisti peptiidi uuringutest
What is Ipamorelin? It is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that activates the ghrelin receptor (GHS-R1a) and was described in 1998 as a selective growth hormone secretagogue. This guide covers its structure, receptor pharmacology, how it differs from related peptides and what the evidence shows.
Peamised järeldused
- Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with the formula C38H49N9O5 and a molecular weight of 711.9 g/mol.
- It acts as an agonist at the ghrelin receptor, GHS-R1a, and was developed under the code NNC 26-0161.
- Raun et al. (1998) described it as the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH.
- It contains non-standard residues (Aib, D-2-Nal, D-Phe), so identity testing must check stereochemistry as well as mass.
Mis on ipamoreliin?
So, what is Ipamorelin? Ipamorelin is a synthetic pentapeptide and ghrelin mimetic. PubChem describes it as binding the ghrelin receptor, also called the growth hormone secretagogue receptor (GHSR), and stimulating growth hormone release from the pituitary (PubChem). Its development code is NNC 26-0161.
Ainult teadusuuringuteks. Käesolev ülevaade võtab kokku avaldatud laboratoorsed ja loomkatsed. Baltic Peptides tarnib seda ühendit kvalifitseeritud teadlaste poolt läbiviidavateks in vitro ja prekliinilisteks uuringuteks; see ei ole ravim ega ole mõeldud kasutamiseks inimestel ega loomadel.
Keemiline struktuur ja tehnilised andmed
| Kinnisvara | Väärtus |
|---|---|
| Jada | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Pikkus | 5 residues, C-terminal amide |
| Molekulivalem | C38H49N9O5 |
| Molekulmass | 711.9 g/mol (average); 711.386 Da monoisotopic, calculated |
| CAS-number | 170851-70-4 |
| PubChemi CID-number | 9831659 |
These values match the PubChem record. Three non-standard features define it. Aib (2-aminoisobutyric acid) is at position 1, D-2-naphthylalanine at position 3 and D-phenylalanine at position 4. It contains no cysteine, methionine or tryptophan, so it lacks the most oxidation-prone residues.
Avastamise ja uurimistöö ajalugu
Raun et al. (1998, Eur J Endocrinol) described ipamorelin as the first selective growth hormone secretagogue. In their conclusion, it is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The compound was derived from the growth hormone-releasing peptide family but optimised for narrower activity.
A pharmacokinetic-pharmacodynamic study in human volunteers followed (Pharm Res, 1999). Beyond that early work, the published human record is limited.
Mechanism: GHS-R1a agonism
Receptor and signalling
Ipamorelin binds GHS-R1a, a G protein-coupled receptor on pituitary somatotrophs. Activation couples through Gq/11 to intracellular calcium and GH secretion. This is the same receptor activated by the endogenous hormone ghrelin.
Selektiivsus
The original work compared ipamorelin with GHRP-6 in rat pituitary cells and animals, and its reported distinction is a narrower endocrine profile, with less effect on other pituitary hormones than earlier GHRPs. Selectivity is a pharmacological finding in the models used, not a safety conclusion.
Peamised uurimisvaldkonnad
- Receptor pharmacology: GHS-R1a binding, Gq/11 signalling and calcium assays in pituitary cell models.
- Selectivity benchmarking: comparison with GHRP-2, GHRP-6 and other ghrelin mimetics.
- GH axis studies: somatotroph responsiveness, GH pulse characteristics and IGF-1 downstream.
- Combination designs: studies pairing a GHRH analogue with a GHS-R1a agonist.
Mida avaldatud uuringud tegelikult näitavad
| Tõendite liik | Millest teatatakse |
|---|---|
| Keemilised faktid | Sequence, formula, mass and CAS number are database-verifiable. |
| Raku-uuringud | GHS-R1a agonism and GH release in rat pituitary cells. |
| Loomkatsed | GH release in rats and swine, compared with GHRP-6. |
| Inimestel läbiviidavad uuringud | An early pharmacokinetic and pharmacodynamic study in volunteers; no approved indication is known. |
| Kinnitamata | Long-term effects, and any benefit outside experimental settings. |
Most of the primary pharmacology dates from the late 1990s, so recent independent replication is limited.
Teaduslikud piirangud ja lahtised küsimused
- The core pharmacology rests on a 1998 paper and a small number of follow-ups.
- Selectivity was shown in the specific models and doses tested.
- Human data are limited, and no approved indication is known.
- GH-releasing peptides are covered by section S2 of the WADA Prohibited List.
- Receptor desensitisation and long-term effects are not well characterised in the sources reviewed here.
Analüütilised ja laboratoorsed aspektid
The two D-residues matter analytically: an L-isomer at either position has the same mass but different receptor activity, so reverse-phase HPLC should resolve diastereomeric impurities. Mass spectrometry should show the intact pentapeptide at about 711.9 Da, including Aib and the C-terminal amide.
With no oxidation-prone residues it is relatively robust, but standard cold, dry storage still applies. See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the Ipamorelin product page.
Allikad ja täiendav kirjandus
- Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 139(5):552-561. PubMed
- Pharmacokinetic-pharmacodynamic modelling of ipamorelin in human volunteers. Pharm Res 16(9):1412-1416 (1999). PubMed
- PubChem compound record for ipamorelin (CID 9831659). PubChem
- WADA Prohibited List, section S2. WADA
Kõik „ Baltic Peptides ” tooted on mõeldud kasutamiseks üksnes laboratoorsetes uuringutes. Need ei ole ravimid, toidulisandid ega toiduained ning neid ei tohi kasutada inimeste ega loomade puhul. Käesolev artikkel võtab kokku avaldatud uuringud üksnes hariduslikel eesmärkidel ega kirjeldada nende kasutamist inimeste puhul.
KKK
Korduma kippuvad küsimused
Mis on ipamoreliin?
What is the sequence of Ipamorelin?
What is the molecular weight and CAS number of Ipamorelin?
Which receptor does Ipamorelin act on?
Why was Ipamorelin called a selective growth hormone secretagogue?
How is Ipamorelin different from Sermorelin and CJC-1295?
Is Ipamorelin an approved medicine?
Loe edasi
Soovitatav lugemine
Ipamoreliin
Current batches, formats and the COA for Ipamorelin.
What is CJC-1295 No DAC?
The GHRH-receptor analogue most often studied alongside ipamorelin.
Peptiidisegude selgitus
Miks komponentide uurimine ei määratle kombineeritud koostist?
Research-grade Ipamorelin, tested before it ships
Iga EList väljasaadetud partii kohta on esitatud sõltumatu laboratooriumi HPLC ja massispektromeetria tulemused.
